Whalen Wealth Management Inc. Buys Shares of 3,677 Illumina, Inc. (NASDAQ:ILMN)

Whalen Wealth Management Inc. acquired a new stake in Illumina, Inc. (NASDAQ:ILMN) during the third quarter, according to its most recent filing with the SEC. The firm acquired 3,677 shares of the life sciences company’s stock, valued at approximately $480,000.

Other large investors also recently bought and sold shares of the company. Primecap Management Co. CA increased its stake in shares of Illumina by 462.5% during the second quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock worth $253,514,000 after acquiring an additional 1,997,010 shares during the period. Millennium Management LLC raised its position in Illumina by 305.0% in the second quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock worth $155,067,000 after acquiring an additional 1,118,747 shares in the last quarter. Capital World Investors lifted its holdings in Illumina by 41.1% in the first quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company’s stock valued at $378,111,000 after acquiring an additional 801,814 shares during the period. Marshall Wace LLP purchased a new stake in shares of Illumina during the 2nd quarter worth $77,628,000. Finally, Swedbank AB acquired a new position in shares of Illumina during the 1st quarter worth $99,682,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Trading Down 3.2 %

NASDAQ ILMN opened at $130.74 on Tuesday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. Illumina, Inc. has a one year low of $93.39 and a one year high of $156.66. The company’s 50 day moving average price is $139.82 and its 200 day moving average price is $124.35.

Illumina (NASDAQ:ILMN) last posted its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same quarter in the previous year, the business posted $0.33 EPS. The business’s quarterly revenue was down 3.5% on a year-over-year basis. As a group, equities research analysts forecast that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on ILMN. JPMorgan Chase & Co. raised their price objective on shares of Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Robert W. Baird lifted their price target on shares of Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. Daiwa Capital Markets upgraded Illumina from a “neutral” rating to a “buy” rating and upped their price target for the stock from $120.00 to $154.00 in a report on Friday, August 16th. Royal Bank of Canada raised their price objective on Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. Finally, Leerink Partners boosted their target price on Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Illumina has a consensus rating of “Moderate Buy” and a consensus target price of $164.00.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.